MAPT and Alzheimer disease: In the clinical practice, the identification of AD-affected individuals is facilitated by measuring the levels of cerebrospinal fluid (CSF) core AD biomarkers, namely total tau (t-tau), threonine-181-phosphorylated-tau (p-tau) proteins, and amyloid beta 1–42 peptide (Aβ42) (Blennow et al., 2010).